{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:07:59Z","timestamp":1791472079367,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100103","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T18:05:44Z","timestamp":1744826744000},"page":"100103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: a real-world experience"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4318","authenticated-orcid":false,"given":"Neha","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhwani","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":false,"given":"Carlyn R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-839X","authenticated-orcid":false,"given":"David J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3291-286X","authenticated-orcid":false,"given":"Oscar B.","family":"Lahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nemirovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-9320","authenticated-orcid":false,"given":"Ross S.","family":"Firestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresia","family":"Akhlaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala","family":"Shekarkhand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-702X","authenticated-orcid":false,"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bneo.2025.100103_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100103_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.bneo.2025.100103_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bneo.2025.100103_bib4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bneo.2025.100103_bib5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100103_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.bneo.2025.100103_bib7","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.bneo.2025.100103_bib8","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.bneo.2025.100103_bib9","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100103_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2025.100103_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2025.100103_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40487-022-00212-5","article-title":"Real-world outcomes of belantamab mafodotin for relapsed\/refractory multiple myeloma (RRMM): preliminary results of a Spanish Expanded Access Program (EAP)","volume":"11","author":"Alegre","year":"2023","journal-title":"Oncol Ther"},{"issue":"12","key":"10.1016\/j.bneo.2025.100103_bib13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.clml.2022.08.003","article-title":"Belantamab in combination with dexamethasone in patients with triple-class relapsed\/refractory multiple myeloma","volume":"22","author":"Atieh","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.bneo.2025.100103_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112964","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: results of the Compassionate Use or the Expanded Access Program in Spain","volume":"15","author":"de la Rubia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bneo.2025.100103_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1026251","article-title":"Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: a multicentric real-life experience","volume":"12","author":"Iula","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100103_bib16","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1002\/ajh.26728","article-title":"Corneal toxicity with belantamab mafodotin: multi-institutional real-life experience","volume":"97","author":"Mohan","year":"2022","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.bneo.2025.100103_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411829","article-title":"Real-world effectiveness and safety of belantamab mafodotin monotherapy in triple-class refractory multiple myeloma","volume":"24","author":"Ntanasis-Stathopoulos","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.bneo.2025.100103_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/ejh.14222","article-title":"Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: the ALFA study","volume":"113","author":"Roussel","year":"2024","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100103_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: a multicentre retrospective study","volume":"200","author":"Shragai","year":"2023","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100103_bib20","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3324\/haematol.2022.281772","article-title":"Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study","volume":"108","author":"Talbot","year":"2023","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.bneo.2025.100103_bib21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"\"Real-life\" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience","volume":"11","author":"Vaxman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.bneo.2025.100103_bib22","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100103_bib23","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100103_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.bneo.2025.100103_bib25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.bneo.2025.100103_bib26","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of real-world data on overall survival in multiple myeloma patients with >\/=3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD","volume":"21","author":"Usmani","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bneo.2025.100103_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41408-023-00946-z","article-title":"Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database","volume":"13","author":"Visram","year":"2023","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.bneo.2025.100103_bib28","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100103_bib29","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2019-129582","article-title":"Response to Bcma CAR-T cells correlates with pretreatment target antigen density and is improved by small molecule inhibition of gamma secretase","volume":"134","author":"Green","year":"2019","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2025.100103_bib30","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1200\/JCO.2022.40.16_suppl.8019","article-title":"Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-5 study","volume":"40","author":"Lonial","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.bneo.2025.100103_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41591-023-02703-y","article-title":"Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial","volume":"30","author":"Trudel","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.bneo.2025.100103_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100103_bib33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.bneo.2025.100103_bib34","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100103_bib35","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2021-152224","article-title":"Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14","volume":"138","author":"Hultcrantz","year":"2021","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.bneo.2025.100103_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970836.36618.0e","article-title":"DREAMM-20: a study to investigate the safety and efficacy of belantamab for the treatment of multiple myeloma when used as monotherapy and in combination treatments [abstract]","volume":"7","author":"Quach","year":"2023","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.bneo.2025.100103_bib37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2025.100103_bib38","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.bneo.2025.100103_bib39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.bneo.2025.100103_bib40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bneo.2025.100103_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802500038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802500038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:10:08Z","timestamp":1756127408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032802500038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S295032802500038X"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100103","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: a real-world experience","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100103"}}